MDS to Wind Down Mass Spec and LC Operations in Montreal to Hasten FDA Investigation | GenomeWeb

NEW YORK, March 31 (GenomeWeb News) - MDS will voluntarily and temporarily wind down all its commercial bioanalytical liquid chromatography and mass spectrometry operations in Montreal in order to accelerate a review by the US Food and Drug Administration, the company announced today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.